Restart Life Sciences Corp.
NMLSF
$0.07
-$0.01-14.29%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -11.84% | 102.63% | 130.58% | 87.15% | 37.44% |
| Depreciation & Amortization | 153.33% | -25.00% | -23.53% | -22.22% | -21.05% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.09% | 102.75% | 130.24% | 87.06% | 31.29% |
| Operating Income | 16.91% | -102.75% | -118.67% | -87.22% | -31.38% |
| Income Before Tax | -116.08% | -700.86% | -9,169.79% | 18.06% | 51.95% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -116.08% | -700.86% | -9,169.79% | 18.06% | 51.95% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -116.08% | -700.86% | -9,169.79% | 18.06% | 51.95% |
| EBIT | 16.91% | -102.75% | -118.67% | -87.22% | -31.38% |
| EBITDA | 16.98% | -103.20% | -119.31% | -87.64% | -31.55% |
| EPS Basic | -406.45% | -399.09% | -6,100.00% | 90.48% | 92.67% |
| Normalized Basic EPS | 58.80% | 2.65% | -31.03% | -23.98% | 5.30% |
| EPS Diluted | -272.73% | -630.14% | -383.78% | 85.33% | 87.38% |
| Normalized Diluted EPS | 57.08% | -2.79% | -27.91% | -18.88% | 9.09% |
| Average Basic Shares Outstanding | 126.28% | 121.69% | 90.80% | 55.51% | 23.90% |
| Average Diluted Shares Outstanding | 119.32% | 113.59% | 92.29% | 59.43% | 27.83% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |